A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>

Aim. To study the efficacy and safety of a two-week bismuth-based quadruple of Helicobacter pylori (Hp) infection with the inclusion of a probiotic Bifiform. Materials and methods. An open prospective comparative randomized study included 68 Hp-positive patients: 22 with a confirmed diagnosis of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emilia P. Yakovenko, Tatiana V. Strokova, Andrew V. Iakovenko, Alexander N. Ivanov, Irina P. Soluyanova, Nikolay N. Vasilyev
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	helicobacter pylori chronic gastritis peptic ulcer eradication triple therapy adverse events plasma cells secretory iga bismuth-containing preparations bifiform Medicine R
Acceso en línea:	https://doaj.org/article/4cf241f13f06414aa0a3347cdd081944
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4cf241f13f06414aa0a3347cdd081944
record_format	dspace
spelling	oai:doaj.org-article:4cf241f13f06414aa0a3347cdd0819442021-12-01T12:22:36ZA prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>0040-36602309-534210.26442/00403660.2021.08.200996https://doaj.org/article/4cf241f13f06414aa0a3347cdd0819442021-08-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/79516/60139https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Aim. To study the efficacy and safety of a two-week bismuth-based quadruple of Helicobacter pylori (Hp) infection with the inclusion of a probiotic Bifiform. Materials and methods. An open prospective comparative randomized study included 68 Hp-positive patients: 22 with a confirmed diagnosis of peptic ulcer disease, 46 with chronic gastritis, gastroduodenitis and erosions in the pylorobulbar zone. The diagnosis and Hp infection were verified by the results of endoscopic and morphological studies, as well as using the 13C-urease breath test and determination of the Hp antigen in the feces. Depending on the therapy, the patients were randomized into 2 groups: the main group was taken 2 times a day for 14 days omeprazole 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth tripotassium dicitrate 240 mg + Bifiform 2 capsules 2 times a day; control similar therapy was carried out, but without the inclusion of Bifiform. Repeated testing for Нр was carried out one month after the termination of the course of treatment. Results. When using bismuth-containing quadruple, a high frequency of Hp eradication was noted, which in the ITT analysis was 86.1 and 68.8% (p0.05) and in the PP analysis it was 93.9 and 95.7% (p0.05) in patients of the main and control groups, respectively. Side effects of drug therapy were detected in 16.7 and 43.8% (p0.05), which was the reason for the early termination of therapy as a result of their development in 5.6 and 28% (p0.05) in patients of the main and control groups, respectively. The inclusion of the probiotic Bifiform in the eradication triple therapy of Hp infection reduced the frequency of detection of colonic dysbiosis from 27.8 to 3.6% and had a positive effect on the indices of local immunity (increased content of plasma cells in the inflammatory infiltrate and a stable level of secretory immunoglobulin A in coprofiltrate). Conclusion. A prospective, comparative, randomized study has shown that when using a two-week bismuth-based quadruple the eradication rate exceeds 90%. The inclusion of Bifiform in the eradication scheme dramatically reduces the frequency of adverse events and increases patient compliance, and also maintains the protective factors of the gastrointestinal mucosa at a higher level.Emilia P. YakovenkoTatiana V. StrokovaAndrew V. IakovenkoAlexander N. IvanovIrina P. SoluyanovaNikolay N. Vasilyev"Consilium Medicum" Publishing housearticlehelicobacter pylorichronic gastritispeptic ulcereradication triple therapyadverse eventsplasma cellssecretory igabismuth-containing preparationsbififormMedicineRRUТерапевтический архив, Vol 93, Iss 8, Pp 916-922 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	helicobacter pylori chronic gastritis peptic ulcer eradication triple therapy adverse events plasma cells secretory iga bismuth-containing preparations bifiform Medicine R
spellingShingle	helicobacter pylori chronic gastritis peptic ulcer eradication triple therapy adverse events plasma cells secretory iga bismuth-containing preparations bifiform Medicine R Emilia P. Yakovenko Tatiana V. Strokova Andrew V. Iakovenko Alexander N. Ivanov Irina P. Soluyanova Nikolay N. Vasilyev A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>
description	Aim. To study the efficacy and safety of a two-week bismuth-based quadruple of Helicobacter pylori (Hp) infection with the inclusion of a probiotic Bifiform. Materials and methods. An open prospective comparative randomized study included 68 Hp-positive patients: 22 with a confirmed diagnosis of peptic ulcer disease, 46 with chronic gastritis, gastroduodenitis and erosions in the pylorobulbar zone. The diagnosis and Hp infection were verified by the results of endoscopic and morphological studies, as well as using the 13C-urease breath test and determination of the Hp antigen in the feces. Depending on the therapy, the patients were randomized into 2 groups: the main group was taken 2 times a day for 14 days omeprazole 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth tripotassium dicitrate 240 mg + Bifiform 2 capsules 2 times a day; control similar therapy was carried out, but without the inclusion of Bifiform. Repeated testing for Нр was carried out one month after the termination of the course of treatment. Results. When using bismuth-containing quadruple, a high frequency of Hp eradication was noted, which in the ITT analysis was 86.1 and 68.8% (p0.05) and in the PP analysis it was 93.9 and 95.7% (p0.05) in patients of the main and control groups, respectively. Side effects of drug therapy were detected in 16.7 and 43.8% (p0.05), which was the reason for the early termination of therapy as a result of their development in 5.6 and 28% (p0.05) in patients of the main and control groups, respectively. The inclusion of the probiotic Bifiform in the eradication triple therapy of Hp infection reduced the frequency of detection of colonic dysbiosis from 27.8 to 3.6% and had a positive effect on the indices of local immunity (increased content of plasma cells in the inflammatory infiltrate and a stable level of secretory immunoglobulin A in coprofiltrate). Conclusion. A prospective, comparative, randomized study has shown that when using a two-week bismuth-based quadruple the eradication rate exceeds 90%. The inclusion of Bifiform in the eradication scheme dramatically reduces the frequency of adverse events and increases patient compliance, and also maintains the protective factors of the gastrointestinal mucosa at a higher level.
format	article
author	Emilia P. Yakovenko Tatiana V. Strokova Andrew V. Iakovenko Alexander N. Ivanov Irina P. Soluyanova Nikolay N. Vasilyev
author_facet	Emilia P. Yakovenko Tatiana V. Strokova Andrew V. Iakovenko Alexander N. Ivanov Irina P. Soluyanova Nikolay N. Vasilyev
author_sort	Emilia P. Yakovenko
title	A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>
title_short	A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>
title_full	A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>
title_fullStr	A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>
title_full_unstemmed	A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>
title_sort	prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> helicobacter pylori </i> infection with the inclusion of the probiotic containing bifidobacterium longum bb-46 and <i> enterococcus faecium encfa-68 </i>
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/4cf241f13f06414aa0a3347cdd081944
work_keys_str_mv	AT emiliapyakovenko aprospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT tatianavstrokova aprospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT andrewviakovenko aprospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT alexandernivanov aprospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT irinapsoluyanova aprospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT nikolaynvasilyev aprospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT emiliapyakovenko prospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT tatianavstrokova prospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT andrewviakovenko prospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT alexandernivanov prospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT irinapsoluyanova prospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i AT nikolaynvasilyev prospectiverandomizedcomparativestudyoftheefficacyandsafetyofatwoweekbismuthbasedquadrotherapyofihelicobacterpyloriiinfectionwiththeinclusionoftheprobioticcontainingbifidobacteriumlongumbb46andienterococcusfaeciumencfa68i
_version_	1718405171963232256

A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>

Ejemplares similares